Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma

Loretta J. Nastoupil, MD
Published: Thursday, Jun 15, 2017



Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

There has been a phase II study investigating rituximab in combination with pembrolizumab in patients with rituximab-sensitive follicular lymphoma, explains Nastoupil. Most patients have had a median of 2 lines of prior therapy.

The primary endpoint of this study was overall response rate (ORR), states Nastoupil. The secondary endpoints included progression-free survival, overall response, duration of response, and safety. The interim analysis concluded that the ORR was 65%, although most patients saw a complete response.
 


Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

There has been a phase II study investigating rituximab in combination with pembrolizumab in patients with rituximab-sensitive follicular lymphoma, explains Nastoupil. Most patients have had a median of 2 lines of prior therapy.

The primary endpoint of this study was overall response rate (ORR), states Nastoupil. The secondary endpoints included progression-free survival, overall response, duration of response, and safety. The interim analysis concluded that the ORR was 65%, although most patients saw a complete response.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x